February 2012 Drug Update Information - Pharmacy Benefits ...

More documents

Recommendations

Info

Drug Information Update Table of Contents First-Time Generics First-Time Generics New Drug Entities New Indications FDA News/Bulletins/Advisories/Safety Alerts Studies Recalls Current Drug Shortages Page 3 Page 3-5 Page 5 Page 6-9 Page 9-18 Page 18-24 Page 24-59 2
GENERIC DRUG NAME GENERIC APPROVAL BRAND NAME MANUFACTU URER DATE EPROSARTAN TEVETEN 600 MG MYLAN MESYLATE 600MG TABLET 12/20/11 PNV#79/IRON/ NEEVO DHA FA/LMFOLATE ZERXIS PHARMA GELCAP CA/DH 12/21/11 FELBAMATE WALLACE PHARMA FELBATOL 600 MG/5 ML SUSP 12/21/11 LAMIVUDINE/ ZIDOVUDINE TEVA USA COMBIVIR TABLET 12/27/11 METHYLPHE ENIDATE HCL ER 20MG, 30MG, 40MG ACTAVIS SOUTH RITALIN LA 1/4/12 TRAMADOL HCL 100MG, 200MG, 300MG RHODES PHARMA / RYZOLT ER 12/ /22/11 / SUN PHARMA TABLET 1/3/12 CLOBEX CLOBETASOL ACTAVIS MID ATL / 12/ /30/11 / 0.05% PROPIONATE 0.05% SHAMPOOO SANDOZZ 1/4/12 SHAMPOOO CLOBEX CLOBETASOL ACTAVIS MID ATL / 0.05% 12/ /30/11 / PROPIONATE 0.05% TOPICAL LOTION PADDOCK LABS TOPICAL LOTION 1/3/12 Gruenhaupt, Mark R.Ph. Argus Health Systems, Inc. c2005 Available from: www.argushealth.com [cited January 5, 2012]. Gruenhaupt, Mark R.Ph. Argus Health Systems, Inc. c2005 Available from: www.argushealth.com [cited January 19, 2012]. New Drug Entities DESCRIPTION NARCOTIC ANTITUSS- 1ST GEN. ANTIHISTAMINEDECONGEST BRAND NAME STATUSS GREEN LIQUID GENERIC NAME CHLORCYCLI/ PSEUDOEPHED/ CODEINE STRENGTH 12.5-30-9 NOTES New Combination PEDIATRIC VITAMIN PREPARATIONS TRI-VITAMIN WITH FLUORIDE DROPS PEDI MVI NO.21 WITH FLUORIDE 0.25 MG/ New ML Combination CEREBRAL SPINAL RADIOACTIVE DIAGNOSTICS CERETECC IV VIAL KIT PREP TC- 99M/ EXAMETAZIME 0.5 MG New Entity SYMPATHOMIMETIC AGENTS PHENYL-EPHRINE HCL- NS IV PLAST. BAG PHENYLEPHRINE HCL/ NS/PF 80MG/ 250ML New Strength MULTIVITAMIN PREPARATIONS B-NEXA TABLET VIT B6/FA/ CALCIUM PHOS/ GINGER 40-1.2- 100 New Combination PROTONPUMP INHIBITORS FIRSTOMEPRAZOLE SUSP RECON OMEPRAZOLE 2 MG/ML New Strength and Dosage Form ADRENAL RADIOACTIVE DIAGNOSTICS ADREVIEW IV VIAL IOBENGUANE SULFATEE I-123 10 MCI/ 5ML New Entity 3
Page 1: February 2012 Drug Information Upda
Page 5 and 6: CICLOPIROX/ TOPICAL PEDIPIROX-4 New
Page 7 and 8: [Posted 01/09/2012] ISSUE: Novartis
Page 9 and 10: Studies Article Link: http://www.fd
Page 11 and 12: the use of XARELTO® (rivaroxaban),
Page 13 and 14: acteria. The Food and Drug Administ
Page 15 and 16: Statins raise risk of Type 2 diabet
Page 17 and 18: The Million Women Study, a U.K. pro
Page 19 and 20: Azithromycin 250 mg tablets, 1 card
Page 21 and 22: RECALLING FIRM/MANUFACTURE Recallin
Page 23 and 24: Recalling Firm: Pfizer Us Pharmaceu
Page 25 and 26: 250 mg, 100 count (NDC 00591-3969-0
Page 27 and 28: Sandoz states the shortage is due t
Page 29 and 30: 5 mL ampule (NDC 10019-0033-72) 20
Page 31 and 32: Article Link: http://www.ashp.org/D
Page 33 and 34: Lidocaine 2% (with epinephrine 1:10
Page 35 and 36: Source: http://www.a ashp.org Halop
Page 37 and 38: ecome unavailable for an extended t
Page 39 and 40: American Regent resumed manufacturi
Page 41 and 42: Trandate tablets, Prometheus 100 mg
Page 43 and 44: Article link: http://www.ashp.org/D
Page 45 and 46: Bedford Laboratories has multiple p
Page 47 and 48: Thiothixene capsules, Mylan 2 mg ca
Page 49 and 50: 20 mL vials (NDC 10019-0905-03) - d
Page 51 and 52: 500 mg extended release, 500 count
Page 53 and 54:
1 mg/mL, 4 mL vial (NDC 25021-0781-
Page 55 and 56:
West-Ward states the shortage is du
Page 57 and 58:
150 mL bottle (NDC 63304-0954-02) C
show all

February 2012 Drug Update Information - Pharmacy Benefits ...

Create successful ePaper yourself

Delete template?

Save as template?